<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03975946</url>
  </required_header>
  <id_info>
    <org_study_id>2018-68</org_study_id>
    <secondary_id>2019-A01513-54</secondary_id>
    <secondary_id>RCAPHM18_0384</secondary_id>
    <nct_id>NCT03975946</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerance of RHEOpheresis in the Treatment of Peripheral Artery Disease in Hemodialysis Patients</brief_title>
  <acronym>RHEO-PAD</acronym>
  <official_title>Efficacy and Tolerance of RHEOpheresis in the Treatment of Peripheral Artery Disease in Hemodialysis Patients: a Prospective Randomized Single-blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peripheral arterial disease (PAD) with limb-threatening ischemia (PAD-LTI) involves both
      macrocirculation and microcirculation. Macrocirculatory abnormalities are accessible to
      revascularization techniques (endovascular or surgical) contrary to microcirculatory
      abnormalities. Conservative treatments have limited efficacy in patients with end-stage renal
      disease (ESRD). There is no alternative treatment for patients with PAD-LTI in hemodialysis.

      Rheopheresis is an apheresis technique specifically designed for the treatment of
      microcirculatory disorders in which anomalies of rheology are at the center of
      physiopathology. This double cascade plasma filtration technique reduces plasma viscosity and
      eliminates inflammation mediators which play an essential role in PAD. This technique has
      already shown its effectiveness in a randomized trial in dry Age-related macular degeneration
      (AMD), another pathology of microcirculation. The effectiveness of rheopheresis in PAD-LTI
      has only been reported in a small number of cases.

      This Hypothesis is that the treatment of microcirculation by rheopheresis would improve wound
      healing of the ischemic lesion and/or reduce major amputation and thus the prognosis of the
      affected limb of the patient with PAD-LTI in hemodialysis. This objective is to demonstrate
      the efficacy of rheopheresis, (twelve sessions), to avoid major amputation and reaches
      complete wound healing of ischemic lesion in the dialysis patient population with PAD-LTI.
      This study is prospective, Controlled, Parallel, Randomized, Single blind and Multicentric in
      France (12 French centers).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2020</start_date>
  <completion_date type="Anticipated">June 12, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 12, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>The efficacy will be assessed by a vascular surgeon blinded to the study group during consultation</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of complete wound healing of the ischemic lesions</measure>
    <time_frame>8 months</time_frame>
    <description>Complete wound healing will be assessed clinically by complete epithelialization of the ischemic lesion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of absence of major amputation.</measure>
    <time_frame>8 months</time_frame>
    <description>Major amputation will be defined as above-the-knee amputation (AKAs) and below-the-knee amputation above the ankle (BKAs)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Hemodialysis</condition>
  <arm_group>
    <arm_group_label>the rheopheresis group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>the shamapheresis group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Rheopheresis procedure</intervention_name>
    <description>Rheopheresis is performed using an automated monitor in a double-filtration cascade. Plasma purify from of high molecular weight proteins through a secondary filter is then returned to the patient. This technique is performed in tandem with a hemodialysis monitor.</description>
    <arm_group_label>the rheopheresis group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood Sample</intervention_name>
    <description>Biological analysis</description>
    <arm_group_label>the rheopheresis group</arm_group_label>
    <arm_group_label>the shamapheresis group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Shamapheresis procedure</intervention_name>
    <description>Shamapheresis is performed with the same automated monitor (Plasauto, HemaT company). Extracted plasma is not treated through the secondary filter (Rheofilter) and return to the patient. This technique is performed in tandem with a hemodialysis monitor.</description>
    <arm_group_label>the shamapheresis group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or more

          -  End stage renal disease (ESRD) treated by hemodialysis or hemodiafiltration - PAD-LTI
             with tissue loss and/or wounds (ulcers or gangrene) with at least one of the following
             criterion: arterial pressure assessment at the ankle &lt;70 millimeter of mercury (mmHg),
             or toe pressure 30 mmHg, or transcutaneous oximetry measurements &lt; 40 mmHg

          -  Interventional or surgical revascularization either not technically possible or no
             necessary - Medical insurance - Signed informed consent

        Exclusion Criteria:

          -  Need for revascularization either endovascular (angioplasty) or surgery (bypass) of
             the ischemic lesion area

          -  Pregnancy or breastfeeding

          -  Uncontrolled infection (persistence of fever despite appropriate antibiotic therapy) -
             Life expectancy greater than 1 year - Severe cognitive or psychiatric disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas ROBERT, PH</last_name>
    <phone>491384095</phone>
    <phone_ext>+33</phone_ext>
    <email>thomas.robert@ap-hm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Olivier ARNAUD, Director</last_name>
    <phone>491382747</phone>
    <phone_ext>+33</phone_ext>
    <email>drci@ap-hm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assistance Publique HÃ´pitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas ROBERT, PH</last_name>
      <phone>491384095</phone>
      <phone_ext>+33</phone_ext>
      <email>thomas.robert@ap-hm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jean-Olivier ARNAUD, Director</last_name>
      <phone>491382747</phone>
      <phone_ext>+33</phone_ext>
      <email>drci@ap-hm.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas ROBERT, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>June 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2019</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

